Shots:

• The company has completed enrollment in P-II (PRIMO) dose optimization & expansion study to evaluate Copiktra in 157 patients with r/r PTCL
• The 1EPs of the expansion study are ORR & 2EPs include additional efficacy measures including DoR, PFS, PK & safety. In an interim analysis of 78 patients in the expansion phase with a minimum follow-up of 6mos., ORR (50%); CR rate (32.1%); m-DoR of 233 days, 80% remain on therapy; 47.4% & 19.2% discontinued due to PD & unacceptable toxicity, 6.4% discontinued for stem cell transplant
• Copiktra is a PI3K inhibitor & 1st US approved dual inhibitor of PI3K-delta & PI3K-gamma. The therapy has received FTD for PTCL & ODD for T-cell lymphomas

Ref: PR Newswire | Image: LinkedIn